Krka d.d. (0HLK)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 64.80 |
|---|---|
| 52-week range | 64.80 – 259.83 |
| Return, 1 month / 3 months | +0.0% / +0.0% |
| Return, 1 year / 3 years | +16.3% / +50.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 197.0% |
| Worst drawdown (1 year) | -75.1% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 14.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Krka d.d. is a pharmaceutical company based in Novo Mesto, Slovenia. It develops and makes prescription medicines, over-the-counter products and animal health products, including generic drugs in areas such as cardiovascular and central nervous system treatment. Its customers are patients, doctors, pharmacies and wholesalers, and its products are sold across Central and Eastern Europe as well as in other European and overseas markets. The company also produces some of its active ingredients and finished dose forms at its own manufacturing sites.
The shares are listed on the London Exchange in UK under the code 0HLK, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Krka d.d. (0HLK) trades on the London Exchange in UK. It last closed at EUR 64.80 on 23 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 2,746 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.3% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 8.4% | ||
| From 52-week high | -75.1% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | 16.3% | ||
| 12-month return, skipping the last month | 16.3% | ||
| Stability (higher is calmer) | 3 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 197.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -75.1% | ||
| Liquidity | 4 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 96.7% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 14.0% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.0% |
| 6 months | +16.3% |
| 1 year | +16.3% |
| 3 years | +50.8% |
| 5 years | +83.8% |
Signals
| 50-day / 200-day average | 64.80 / 59.77 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 189.95 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Jul 2026 | EUR 9.1000 |
| 22 Jul 2025 | EUR 8.2500 |
| 23 Jul 2024 | EUR 7.5000 |
| 18 Jul 2023 | EUR 6.6000 |
| 19 Jul 2022 | EUR 5.6300 |
| 20 Jul 2021 | EUR 5.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.